Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.

Myxoid and round cell liposarcoma represents a morphological spectrum in which tumor progression from low-grade myxoid to high-grade round cell areas is frequently observed. A distinctive t(12;16)(q13;p11) reciprocal translocation rearranges the CHOP gene localized to 12q13 in most cases. Data concerning the occurrence of cell cycle aberrations in this subset of mesenchymal malignancies are very limited. Therefore, we analyzed a histologically homogeneous series of 21 cases of myxoid and round cell liposarcoma. The p53 pathway was studied by investigating the TP53 gene and protein, mdm2 protein, and p21Waf1 protein. The Rb-cyclin D pathway was analyzed by studying the pRb protein, the p16MTS1 gene, cyclin D1, cyclin D3, p27Kip1, cdk4, and cdk6 proteins. In contrast with the rare involvement of the TP53 gene in well differentiated liposarcoma, aberrations of the TP53 gene were observed in approximately 30% of cases of myxoid and round cell liposarcoma. Notably, mdm2 overexpression was seen in 56% of cases and correlated with histological grade, therefore indicating a possible role in tumor progression. Abnormalities involving the Rb-cyclin D pathway were observed in more than 90% of cases. pRb loss was present in one-third of cases and, at variance with that observed in other subsets of sarcoma, overexpression of cyclin Ds represented a rare event. Interestingly, upregulation of either cdk4 or cdk6 was demonstrated in 85% of cases.

[1]  F. Mitelman,et al.  Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features , 1997, The Journal of pathology.

[2]  C. Fletcher Will We Ever Reliably Predict Prognosis in a Patient with Myxoid and Round Cell Liposarcoma? , 1997 .

[3]  F. Rilke,et al.  DISTINCT mdm2/p53 EXPRESSION PATTERNS IN LIPOSARCOMA SUBGROUPS: IMPLICATIONS FOR DIFFERENT PATHOGENETIC MECHANISMS , 1997, The Journal of pathology.

[4]  A. D. Dei Tos,et al.  MOLECULAR ABNORMALITIES OF THE p53 PATHWAY IN DEDIFFERENTIATED LIPOSARCOMA , 1997, The Journal of pathology.

[5]  C. Sherr Cancer Cell Cycles , 1996, Science.

[6]  P. Meltzer,et al.  Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas , 1996, Genes, chromosomes & cancer.

[7]  M. Barbareschi,et al.  p21/WAF1/CIP1 EXPRESSION IN NORMAL MUCOSA AND IN ADENOMAS AND ADENOCARCINOMAS OF THE COLON: ITS RELATIONSHIP WITH DIFFERENTIATION , 1996, The Journal of pathology.

[8]  F. Sim,et al.  The clinicopathologic spectrum of myxoid and round cell liposarcoma: A study of 95 cases , 1996, Cancer.

[9]  A. D. Dei Tos,et al.  Tumor suppressor genes and related molecules in leiomyosarcoma. , 1996, The American journal of pathology.

[10]  M. Höglund,et al.  Fusion of the EWS and CHOP genes in myxoid liposarcoma. , 1996, Oncogene.

[11]  J. Goldblum,et al.  Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. , 1996, The American journal of surgical pathology.

[12]  M. Sasaki,et al.  MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors , 1995, International journal of cancer.

[13]  R. Beart,et al.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.

[14]  C. Cordon-Cardo,et al.  Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. , 1995, British Journal of Cancer.

[15]  C. Cordon-Cardo Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[16]  E. Hovig,et al.  Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. , 1995, British Journal of Cancer.

[17]  J. Fletcher,et al.  Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains , 1995, Cell.

[18]  Tony Kouzarides,et al.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein , 1995, Nature.

[19]  W. Sellers,et al.  Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.

[20]  A. Marchetti,et al.  mdm2 gene alterations and mdm2 protein expression in breast carcinomas , 1995, The Journal of pathology.

[21]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[22]  A. D. Dei Tos,et al.  Spindle Cell Liposarcoma, A Hitherto Unrecognized Variant of Liposarcoma Analysis of Six Cases , 1994, The American journal of surgical pathology.

[23]  R. Sclafani,et al.  Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Cordon-Cardo,et al.  Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. , 1994, The American journal of pathology.

[25]  D. Givol,et al.  Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.

[26]  A. D. Dei Tos,et al.  Ultraviolet-induced p53 mutations in atypical fibroxanthoma. , 1994, The American journal of pathology.

[27]  B. Gusterson,et al.  Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. , 1994, British Journal of Cancer.

[28]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[29]  J. Bartek,et al.  Cyclin D1 expression is regulated by the retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[31]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[32]  P. Meltzer,et al.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.

[33]  E. Hovig,et al.  p53 abnormalities in different subtypes of human sarcomas. , 1993, Cancer research.

[34]  T. Triche,et al.  Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas. , 1993, Journal of the National Cancer Institute.

[35]  C. Fletcher,et al.  p53 protein expression in non‐neoplastic lesions and benign and malignant neoplasms of soft tissue , 1993, Histopathology.

[36]  R. Weichselbaum,et al.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. , 1992, Cancer research.

[37]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[38]  R. Maestro,et al.  High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. , 1992, Oncogene.

[39]  N. Harris,et al.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Stratton,et al.  Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. , 1990, Oncogene.

[41]  R. Eddy,et al.  Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. , 1989, The Journal of clinical investigation.

[42]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Goldblum,et al.  Immunohistochemical analysis of p53 protein in myxoid/round-cell liposarcoma of the extremities , 1996 .

[44]  C. Fletcher,et al.  Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. , 1995, Cancer research.